Unknown

Dataset Information

0

Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.


ABSTRACT: Current guidelines do not recommend screening for non-alcoholic fatty liver disease (NAFLD) or advanced fibrosis. Patients with type 2 diabetes mellitus (T2DM) are known to be at increased risk for NAFLD and advanced fibrosis.To assess the feasibility in diabetics in a primary care setting of screening for NAFLD and advanced fibrosis, by using non-invasive magnetic resonance imaging (MRI) to estimate the hepatic proton density fat fraction (MRI-PDFF) and magnetic resonance elastography (MRE) to estimate hepatic stiffness.We performed a cross-sectional analysis of a prospective study that included 100 (53% men) consecutively enrolled diabetics who did not have any other aetiology of liver disease. All patients underwent a standardised research visit, laboratory tests, MRI-PDFF, and MRE.Mean (±s.d.) age and body mass index (BMI) was 59.7 (±11.2) years and 30.8 (±6.5) kg/m(2) , respectively. The prevalence of NAFLD (defined as MRI-PDFF ?5%) and advanced fibrosis (defined as MRE ?3.6 kPa) was 65% and 7.1%, respectively. One patient with advanced fibrosis had definite hepatocellular carcinoma. When compared to those without NAFLD, patients with NAFLD were younger (P = 0.028) and had higher mean BMI (P = 0.0008), waist circumference (P < 0.0001) and prevalence of metabolic syndrome (84.6% vs. 40.0%, P < 0.0001). Only 26% of those with NAFLD had elevated alanine aminotransferase.This proof-of-concept study demonstrates that T2DM has significant rates of both NAFLD and advanced fibrosis. Concomitant screening for NAFLD and advanced fibrosis by using MRI-proton density fat fraction and magnetic resonance elastography in T2DM is feasible and may be considered after validation in a larger cohort.

SUBMITTER: Doycheva I 

PROVIDER: S-EPMC4673036 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.

Doycheva I I   Cui J J   Nguyen P P   Costa E A EA   Hooker J J   Hofflich H H   Bettencourt R R   Brouha S S   Sirlin C B CB   Loomba R R  

Alimentary pharmacology & therapeutics 20150915 1


<h4>Background</h4>Current guidelines do not recommend screening for non-alcoholic fatty liver disease (NAFLD) or advanced fibrosis. Patients with type 2 diabetes mellitus (T2DM) are known to be at increased risk for NAFLD and advanced fibrosis.<h4>Aim</h4>To assess the feasibility in diabetics in a primary care setting of screening for NAFLD and advanced fibrosis, by using non-invasive magnetic resonance imaging (MRI) to estimate the hepatic proton density fat fraction (MRI-PDFF) and magnetic r  ...[more]

Similar Datasets

| S-EPMC3608644 | biostudies-literature
| S-EPMC4764354 | biostudies-literature
| S-EPMC8458479 | biostudies-literature
| S-EPMC3922891 | biostudies-literature
| S-EPMC7026172 | biostudies-literature
| S-EPMC6590281 | biostudies-literature
| S-EPMC9396333 | biostudies-literature
| S-EPMC8470742 | biostudies-literature
| S-EPMC7880972 | biostudies-literature
| S-EPMC8056630 | biostudies-literature